 Recro Pharma Inc NASDAQ: REPH has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health NIH. The new contract is an individual 1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired. 